What is Infinium Pharmachem Ltd (INFINIUM) share price return in the past 10 years?

Data is not available for this company

What is the share price of Infinium Pharmachem Ltd (INFINIUM)?

Company share prices are keep on changing according to the market conditions. The current trading price of Infinium Pharmachem Ltd (INFINIUM) on 01-Jan-1970 05:30:00 at 05:30 is .

What is the P/E ratio of Infinium Pharmachem?

The latest standalone P/E ratio of Infinium Pharmachem as of 01-Jan-1970 is 31.78.

What is the P/B ratio of Infinium Pharmachem Ltd (INFINIUM)?

The latest standalone P/B ratio of Infinium Pharmachem Ltd (INFINIUM) as of 01-Jan-1970 is 3.01.

What is the 52-week high and low of Infinium Pharmachem Ltd (INFINIUM)?

The 52-week high of Infinium Pharmachem Ltd (INFINIUM) is Rs. 0.00 and the 52-week low is Rs. 0.00.

Infinium Pharmachem Ltd (INFINIUM) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Infinium Pharmachem Ltd (INFINIUM)
Brand: Infinium Pharmachem

Infinium Pharmachem Ltd (INFINIUM)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: INFINIUM Chemicals | Small Cap | Infinium Pharmachem Share Price

Infinium Pharmachem Ltd (INFINIUM)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: INFINIUM Chemicals | Small Cap | Infinium Pharmachem Share Price

Key Metrics

Valuation Multiples

Market Cap

₹318 Cr.

Current Price

₹0

52-Week Low / High

₹0 / 0

TTM EPS

₹6.4

TTM Sales

₹156 Cr.

Book Value per Share

₹67.8

P/E Ratio

31.78

Lower than its 5-year historical median

Industry PE

52.9

Price to Book (P/B)

3.01

Lower than its 5-year historical median

Price to Sales (P/S)

2.04

Lower than its 5-year historical median

EV/EBITDA

17.98

Lower than its 5-year historical median

Dividend Yield

NAN%

Profitability Efficiency

Return on Equity (ROE)

10.36%

In line with industry median

Return on Capital Employed (ROCE)

13.22%

In line with industry median

Return on Assets (ROA)

6.95%

Operating Profit Margin

11.1%

Net Profit Margin

6.19%

Gross Profit Margin

10.7%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

11.9%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

-12.86%

Net Profit Growth (1 Year)

Slowing versus 3-year growth rate

-23.62%

Asset Quality

Promoter Holding

64.91%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹90 Cr.

Equity

₹15.6 Cr.

Face Value

₹10

All Time Low / High

- / -

Infinium Pharmachem stock performance

Key Ratios

Check Before You Invest

Quality

Locked

Valuation

Locked

Price Trend

Locked

Q.1 Is Infinium Pharmachem Ltd a good quality company?

Infinium Pharmachem Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Infinium Pharmachem Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Infinium Pharmachem Ltd vs industry peers?

Infinium Pharmachem Ltd revenue CAGR is 30.60%, compared to the industry median CAGR of 7.53%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Infinium Pharmachem Ltd?

Promoters hold 64.91% of the Infinium Pharmachem Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Infinium Pharmachem Ltd over the last decade?

Over the last 3 year(s), the stock has delivered a CAGR of -8.31% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	19.9%	31.8%	34.4%	36.8%	29.3%	13.2%	-
Value Creation Index ⓘ	0.4	1.3	1.5	1.6	1.1	-0.1	-
Growth Parameters ⓘ
Sales ⓘ	36	54.6	74	101	122	137	156
Sales YoY Gr.	-	51.4%	35.7%	36.8%	20.8%	11.9%	-
Adj EPS ⓘ	1	2.4	5.3	8.3	7.6	5	6.4
YoY Gr.	-	154.7%	117.8%	57.7%	-8.2%	-34.5%	-
BVPS (₹) ⓘ	4.3	6.9	12.3	21.3	41.5	67.8	67.8
Adj Net Profit ⓘ	1	2.5	5.4	8.5	10.6	7.8	10
Cash Flow from Ops. ⓘ	2.3	6.8	9.1	7.4	3.1	-26	-
Debt/CF from Ops. ⓘ	3.8	1.5	2.5	3.6	2.5	-1.8	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	NA	30.6%	22.7%	11.9%
Adj EPS ⓘ	NA	39.4%	-1.7%	-34.5%
BVPSⓘ	NA	74%	76.5%	63.5%
Share Price	-	-	-9%	-29.8%

Key Financial Parameters ⓘ

	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	22.4	43.4	54.7	49.4	26.7	9.5	9.5
Op. Profit Mgn % ⓘ	7.3	9	11.8	15	14.2	11.1	NAN
Net Profit Mgn % ⓘ	2.7	4.5	7.2	8.3	8.7	5.7	6.4
Debt to Equity ⓘ	2.1	1.5	1.8	1.2	0.1	0.4	-
Working Cap Days ⓘ	0	124	138	137	140	203	0
Cash Conv. Cycle ⓘ	0	50	54	68	91	127	0

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	36	55	74	101	122	137
Operating Expenses ⓘ +	33	50	65	86	105	122
Manufacturing Costs	1	2	3	3	3	3
Material Costs	27	39	54	71	94	109
Employee Cost	2	2	2	2	3	4
Other Costs ⓘ	3	6	7	11	6	6
Operating Profit ⓘ	3	5	9	15	17	15
Operating Profit Margin (%)	7.3%	9.0%	11.8%	15.0%	14.2%	11.1%
Other Income ⓘ +	1	1	1	1	2	2
Exceptional Items ⓘ	0	0	0	0	0	0
Interest ⓘ	1	1	2	3	2	3
Depreciation ⓘ	1	1	1	1	2	3
Profit Before Tax ⓘ	1	4	7	12	15	12
Tax ⓘ	0	1	2	3	4	3
Profit After Tax	1	3	6	9	11	8
PAT Margin (%)	2.8%	5.0%	7.4%	9.0%	9.1%	6.2%
Adjusted EPS (₹)	1.0	2.7	5.4	9.0	8.0	5.4
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%

Valuation of Infinium Pharmachem - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	4	7	13	22	58	106
Share Capital ⓘ	1	1	1	5	14	16
Reserves ⓘ	3	6	12	17	44	90
Debt +	9	11	22	26	8	39
Long Term Debt	6	6	14	8	5	5
Short Term Debt	3	5	9	18	3	34
Minority Interest	0	0	0	0	0	0
Trade Payables	6	11	10	9	8	11
Others Liabilities ⓘ	1	2	4	4	5	11
Total Liabilities ⓘ	21	31	49	60	78	166
Fixed Assets
Net Fixed Assets ⓘ +	4	4	4	16	16	17
Gross Block	7	8	8	21	24	28
Accumulated Depreciation	3	3	4	5	8	11
CWIP ⓘ	0	4	8	0	0	1
Investments ⓘ	0	0	0	0	0	16
Inventories	7	9	14	18	22	35
Trade Receivables	7	10	13	15	24	34
Cash Equivalents	0	1	2	3	8	33
Others Assets ⓘ	2	2	8	8	6	30
Total Assets ⓘ	21	31	49	60	78	166

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	2	7	9	7	3	-26
PBT ⓘ	1	4	7	12	15	12
Adjustment ⓘ	2	2	2	4	4	6
Changes in Working Capital ⓘ	-0	2	1	-6	-12	-40
Tax Paid ⓘ	-0	-1	-2	-3	-4	-3
Cash Flow From Investing Activity ⓘ +	-1	-5	-7	-3	-3	-23
Capex	-1	-5	-5	-5	-3	-4
Net Investments	0	0	0	-0	0	-15
Others ⓘ	0	0	-2	2	0	-3
Cash Flow From Financing Activity ⓘ +	-1	-1	-2	-3	5	74
Net Proceeds from Shares ⓘ	0	0	0	0	25	41
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0
Interest Paid ⓘ	-1	-1	-2	-3	-2	-3
Dividend Paid ⓘ	0	0	0	0	0	0
Others ⓘ	0	0	0	0	-18	36
Net Cash Flow ⓘ	0	1	0	2	5	25

Financial Ratio

PARTICULARS	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	23.59	47.87	56.17	53.43	27.92	10.36
ROCE (%)	19.87	31.77	34.44	36.83	29.32	13.22
Asset Turnover Ratio	1.75	2.13	1.86	1.85	1.77	1.12
PAT to CFO Conversion(x)	2	2.33	1.5	0.78	0.27	-3.25
Working Capital Days
Receivable Days	75	59.70	57.60	50.60	58.10	77.60
Inventory Days	68.10	51.50	56.40	57.90	60.30	76.90
Payable Days	79.90	80.40	73.10	49.20	31.70	30.60

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Infinium Pharmachem Ltd FAQs

The current trading price of Infinium Pharmachem on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Infinium Pharmachem stood at ₹318.4 Cr

The latest P/E ratio of Infinium Pharmachem as of 31-Dec-1969 is 31.78.

The latest P/B ratio of Infinium Pharmachem as of 31-Dec-1969 is 3.01.

The 52-week high of Infinium Pharmachem is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Infinium Pharmachem is ₹156 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Infinium Pharmachem Ltd is a good quality company.

The key valuation ratios of Infinium Pharmachem Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Infinium Pharmachem Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Infinium Pharmachem Ltd

Infinium Pharmachem is well focused to Iodine chemistry. The company is working as Contract Research and Manufacturing Services (CRAMS), but its domain is very restricted to Iodine chemistry & it revolves around Iodine derivatives or Iodination. Since 2003. the company has been manufacturing & supplying wide range of superior quality iodine derivatives & active pharmaceutical ingredient (API).

The company is also providing fully integrated customized services from R&D to Commercial scale manufacturing and packaging for its products to the Pharmaceutical, Agrochemical, Nutraceutical, Speciality Chemicals & various other chemical Industries. The company supplies range of Iodine derivatives on Order to Made basis only. The company also undertakes Non-Disclosure Agreement (NDA) for the development of confidential and rarely available Iodine compounds.

Business area of the company

The company is engaged in manufacturing and selling of Iodian based Pharmaceutical Intermediates.

Milestones

2003: Established with a vision to be a globally integrated and admired Pharmaceutical and Healthcare Company.
2004: Started iodine derivatives manufacturing plant at Gujarat, India.
2010: Set up R&D Unit and Certified as ISO 90001-2008.
2011: Penetrated the Pharmaceutical market with the CRAMS model.
2014: Upgraded Plant with GMP compliant large scale manufacturing facility.
2015: Obtained FDA approval for manufacturing of APIs.
2017: Certified as WHO-GMP and ISO 14001-2015.
2018: Product Portfolio touched 200+ Iodine Derivatives and 7+ APIs.
2019: Expanded reach to over 15+ countries across the globe.
2021: Augmentation of production capacity and construction of new Premises.
2022: Incorporated subsidiary company in bio-fuel segment for backward integration.
2022: Conversion of the company’s status from Private Limited to Limited Company.
2023: Infinium Pharmachem shares were listed on the NSE SME (Emerge) platform.
2023: Subsidiary Company ‘Infinium Green Energy’, commenced Production facility from May 14, 2023.
2024: Commenced construction activities for its new Project (Area comprised of around 1,114 Sq. Mt.) dedicated to manufacturing contrast media raw materials.
2025: Entered into a 5-year exclusive distribution agreement with K Sakai & Company Limited
2026: Successfully completed and commissioned its new manufacturing facility for contrast media raw materials at GIDC Sojitra, District Anand, Gujarat with effect from January 16, 2026.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Infinium Pharmachem Ltd (INFINIUM)

Infinium Pharmachem Ltd (INFINIUM)

Infinium Pharmachem stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Infinium Pharmachem - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Infinium Pharmachem Ltd FAQs

What is the share price of Infinium Pharmachem?

What is the market cap of Infinium Pharmachem?

What is the P/E ratio of Infinium Pharmachem?

What is the P/B ratio of Infinium Pharmachem?

What is the 52-week high and low of Infinium Pharmachem?

What is the TTM revenue of Infinium Pharmachem?

Is Infinium Pharmachem Ltd a good quality company?

Is Infinium Pharmachem Ltd undervalued or overvalued?

Is Infinium Pharmachem Ltd a good buy now?

About Infinium Pharmachem Ltd

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.